Clinical Trial Update: Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety of ON 01910.Na given as a 3-day infusion in patients with advanced cancer has completed; the document provides safety find…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neoplasms
• Solid Tumors

Drugs mentioned

• ON-01910.Na (ON-01910 sodium)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Advanced Cancer, Solid Tumors | Phase 1 | Status: COMPLETED